What is Zacks Research's Estimate for Masimo Q2 Earnings?

Key Points

• Zacks Research has lowered Masimo's Q2 2026 EPS estimate to $1.33 per share, down from $1.34, with the full-year earnings consensus at $4.10 per share.
• Masimo reported Q2 earnings of $1.33 per share, surpassing estimates of $1.22 and achieving 7.7% revenue growth year-over-year.
• Insider activity has increased as Director William R. Jellison bought 3,000 shares at an average price of $145.98, raising his ownership stake by 167.6%.

Masimo Corporation (NASDAQ:MASI - Free Report) - Equities research analysts at Zacks Research dropped their Q2 2026 EPS estimates for Masimo in a report issued on Monday, August 25th. Zacks Research analyst Team now expects that the medical equipment provider will earn $1.33 per share for the quarter, down from their prior forecast of $1.34. The consensus estimate for Masimo's current full-year earnings is $4.10 per share.

Masimo (NASDAQ:MASI - Get Free Report) last announced its earnings results on Tuesday, August 5th. The medical equipment provider reported $1.33 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.11. The company had revenue of $370.90 million during the quarter, compared to the consensus estimate of $368.65 million. Masimo had a negative net margin of 24.85% and a positive return on equity of 26.54%. Masimo's revenue was up 7.7% compared to the same quarter last year. During the same period last year, the firm earned $0.86 earnings per share.

MASI has been the topic of several other reports. Wells Fargo & Company reduced their target price on Masimo from $205.00 to $190.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. BTIG Research restated a "buy" rating on shares of Masimo in a research note on Thursday, August 14th. Wall Street Zen downgraded shares of Masimo from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Raymond James Financial decreased their price objective on shares of Masimo from $204.00 to $185.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Finally, Piper Sandler boosted their target price on shares of Masimo from $200.00 to $210.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 6th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, Masimo presently has a consensus rating of "Moderate Buy" and an average price target of $193.60.

Masimo Stock Down 0.5%

Masimo stock opened at $142.49 on Thursday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.14 and a quick ratio of 1.61. The stock has a market capitalization of $7.74 billion, a price-to-earnings ratio of -16.72 and a beta of 1.21. Masimo has a 1-year low of $107.98 and a 1-year high of $194.88. The business has a fifty day moving average price of $158.12 and a 200-day moving average price of $162.27.

Insider Activity

In other Masimo news, Director William R. Jellison bought 3,000 shares of the firm's stock in a transaction that occurred on Monday, August 11th. The stock was bought at an average cost of $145.98 per share, for a total transaction of $437,940.00. Following the completion of the transaction, the director directly owned 4,790 shares of the company's stock, valued at approximately $699,244.20. This trade represents a 167.60% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 9.70% of the stock is currently owned by company insiders.

Institutional Trading of Masimo

Hedge funds have recently added to or reduced their stakes in the company. Twin Tree Management LP purchased a new position in Masimo in the first quarter valued at $29,000. MAI Capital Management grew its position in shares of Masimo by 176.7% during the 2nd quarter. MAI Capital Management now owns 202 shares of the medical equipment provider's stock valued at $34,000 after acquiring an additional 129 shares during the period. Farther Finance Advisors LLC grew its position in shares of Masimo by 128.9% during the 1st quarter. Farther Finance Advisors LLC now owns 206 shares of the medical equipment provider's stock valued at $35,000 after acquiring an additional 116 shares during the period. Hilltop National Bank purchased a new position in shares of Masimo in the 2nd quarter valued at about $37,000. Finally, Anderson Financial Strategies LLC acquired a new position in Masimo in the 1st quarter worth about $49,000. 85.96% of the stock is owned by hedge funds and other institutional investors.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.